- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05914337
Exercise on microRNA in Rheumatoid Arthritis
Investigation Into the Effects of Exercise on microRNA Expressions in Patients With Rheumatoid Arthritis
The goal of this prospective cohort study is to learn about whether exercise alters microRNA expression levels in 30 rheumatoid arthritis patients and 30 healthy controls.
The main questions it aims to answer are:
- Does exercise affect microRNA expression levels related to the pathophysiology of rheumatoid arthritis?
- Are microRNA levels correlated with disease activity? Participants was applied program consisting of strengthening and stretching exercises 2 days a week for 8 weeks. One day a week, 30 minutes of mild moderate walking was requested.
Researchers will compare rheumatoid arthritis patients and healthy controls to see if that the microRNA expression levels of patients with rheumatoid arthritis as a result of exercise training would not make a significant difference with healthy controls.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rheumatoid arthritis can be a systemic, inflammatory, autoimmune breathing that can cause heavy, joint destruction with vibrations in the synovial vessels of the joints. Although great strides have been made in understanding the disease, the pathogenesis of Rheumatoid arthritis.A has not yet been fully elucidated. Early treatment can prevent serious disability.
The goal of treatment for patients with rheumatoid arthritis is to achieve remission or at least a state of low disease activity.Combinations with disease-modifying antirheumatic drugs (DMARDs) and biologic agents are recommended for patients who fail to respond to treatment, based on patient prognosis and response to treatment.
In addition to drug therapy, exercise training is recommended in patients with Rheumatoid arthritis. Decreased joint health, including joint pain and inflammation, fatigue, increased incidence of cardiovascular disease in patients with rheumatoid arthritis; it causes functional limitation, disability, comorbidities and a decrease in quality of life.Therefore, it is recommended that aerobic and resistance exercise training should be encouraged as part of the routine treatment of all Rheumatoid arthritis patients.
microRNAs (miRNAs) are small, non-coding RNAs that mediate messenger RNA (mRNA) cleavage, translational repression. As regulators of gene expression, miRNAs participate in critical cellular processes and show varying levels of expression in many cell types in different diseases.It became clear that there were changes in miRNA expression in Rheumatoid arthritis patients.In many studies, it has been shown that miRNAs contribute to the disruption of joint destruction, inflammation and apoptosis in peripheral blood mononuclear cells, isolated T lymphocytes, synovial tissue and synovial fibroblasts. Thus, miRNAs are known to constitute the pathophysiological process specific to Rheumatoid arthritis.
miRNA-146a is one of the miRNAs that has been extensively studied in Rheumatoid arthritis. It was found that the expression of miRNA-146a in the synovial fluid and synovial tissue of Rheumatoid arthritis A patients was significantly higher than in healthy individuals, and miRNA-16 and miRNA-155 together with miRNA-146a may be related to disease pathology. In addition, high levels of miRNA-16 expression are known to correlate with active disease and low expression levels with remission. It has been reported that the expression level of miRNA-145 is increased in peripheral blood mononuclear cells and synovium of Rheumatoid arthritis patients, which supports osteoclastogenesis.
In this study, it was aimed to determine whether miRNAs, which play a role in determining the effectiveness of the treatment and the severity of the disease, change with exercise training, to know the effect of exercise training on the person, to accept it as an auxiliary practice in controlling the disease and to prove it with scientific facts.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Sakarya, Turkey
- Sakarya Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Individuals with not having any deformity in the last six months, not having a diagnosed cardiovascular disease
Exclusion Criteria:
- Exclusion criteria were not giving written consent, severe hypertension that would prevent physical activity, orthopedic problems that would prevent participation in the study, uncontrolled chronic systemic disease, central and peripheral nervous system diseases, recent neurological, orthopedic or other
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Rheumatoid Arthritis Group
30 patients aged 18-60 years who met the 2010 American College of Rheumatology / European League Against Rheumatism Rheumatoid arthritis criteria were included in the study.
A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks.
One day a week, 30 minutes of mild moderate walking was requested.
30 healthy controls aged 18-60 years who included in the study.
Of the cases at the beginning and at the end of the treatment; 5-10 cc peripheral blood samples were taken into one Ethylenediaminetetraacetic acid tube.
Then Numeric Rating Scale (NRS) was used for pain, 28-joint Disease Activity Score (DAS28) was used to calculate disease activity, Health Assessment Questionnaire (HAQ) was used to assess general health and Short Form-36 (SF-36) was used to evaluate quality of life.
In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time polymerase chain reaction method.
|
A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks.
One day a week, 30 minutes of mild moderate walking was requested.
In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time polymerase chain reaction method.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gene Expressions of microRNA for Healthy Control Group
Time Frame: Baseline
|
By examining the expression level of RNA, U6 small nuclear 1 (human) as a control gene, it is decided whether the expression levels of microRNAs are expressed up or down.
|
Baseline
|
|
Pre-Treatment Gene Expressions of microRNA for Treatment Group
Time Frame: Baseline
|
By examining the expression level of RNA, U6 small nuclear 1 (human) as a control gene, it is decided whether the expression levels of microRNAs are expressed up or down.
|
Baseline
|
|
Pre-Treatment DAS28 for Treatment Group
Time Frame: Baseline
|
28-joint Disease Activity Score (DAS28), which is widely used in clinics, is used to find disease findings in patients with rheumatoid arthritis.
Calculation is made with the C-Reactive Protein value.
DAS28> 5.1 is considered high disease activity, 3.2<DAS28≤5.1 is considered moderate disease activity, DAS28≤3.2 is low disease activity, and DAS28<2.6 is considered disease remission.
|
Baseline
|
|
Post-Treatment DAS28 for Treatment Group
Time Frame: Through study completion, an average of 2 months
|
28-joint Disease Activity Score (DAS28), which is widely used in clinics, is used to find disease findings in patients with rheumatoid arthritis.
Calculation is made with the C-Reactive Protein value.
DAS28> 5.1 is considered high disease activity, 3.2<DAS28≤5.1 is considered moderate disease activity, DAS28≤3.2 is low disease activity, and DAS28<2.6 is considered disease remission.
|
Through study completion, an average of 2 months
|
|
Post-Treatment Gene Expressions of microRNA for Treatment Group
Time Frame: Through study completion, an average of 2 months
|
By examining the expression level of RNA, U6 small nuclear 1 (human) as a control gene, it is decided whether the expression levels of microRNAs are expressed up or down.
|
Through study completion, an average of 2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NRS
Time Frame: at the beginning of the intervention and through study completion, an average of 2 month
|
Then Numeric Rating Scale (NRS) was used for pain.
In this scale, pain intensity is measured with an 11-point scale.
Here 0: No pain and 10: the most severe pain level.
|
at the beginning of the intervention and through study completion, an average of 2 month
|
|
HAQ
Time Frame: at the beginning of the intervention and through study completion, an average of 2 month
|
Health Assessment Questionnaire was used to assess general health.
It consists of 20 questions in total, including 8 subsections.
Subjects score between 0-3 according to their level of difficulty in activities.
The total score is obtained by calculating the arithmetic mean of the sums of the highest scores in the subsections.
Higher scores indicate higher functional disability and pain.
|
at the beginning of the intervention and through study completion, an average of 2 month
|
|
SF-36
Time Frame: at the beginning of the intervention and through study completion, an average of 2 month
|
Short Form-36 (SF-36) was used to evaluate quality of life.
This Questionnaire consists of eight subsections.
Scoring is made between 0-100 for each of the subsections.
Higher scores indicate better function and well-being.
|
at the beginning of the intervention and through study completion, an average of 2 month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Fulya Senem KARAAHMETOĞLU, M. Sc., Saglik Bilimleri Universitesi
- Study Chair: Zeynep Betül ÖZCAN, M. Sc., Saglik Bilimleri Universitesi
- Study Chair: Sibel KURAŞ, M. Sc., Saglik Bilimleri Universitesi
- Study Chair: Bekir ERDOĞAN, M. Sc., Saglik Bilimleri Universitesi
- Principal Investigator: Mehmet Zahid ÇIRACI, MD, Sakarya Training and Research Hospital
- Study Chair: Halime Hanım PENÇE, Assoc. Pr, Saglik Bilimleri Universitesi
- Study Chair: Meltem VURAL, Prof. Dr., Istanbul Bakırköy Dr.Sadi Konuk Training and Research Hospital
- Study Chair: Alev KURAL, Assoc. Pr., Istanbul Bakırköy Dr.Sadi Konuk Training and Research Hospital
- Study Chair: Işıl ÜSTÜN, MD, Istanbul Bakırköy Dr.Sadi Konuk Training and Research Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RA_miRNA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
Yuanyuan ZhangRecruitingRheumatoid Arthritis (RA) | Rheumatoid Arthritis-Associated Interstitial Lung Disease | Difficult-to-Treat Rheumatoid ArthritisChina
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Richard Burt, MDTerminated
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
University Hospital, ToulouseCompletedRheumatoId ArthritisFrance
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on exercise
-
National Institute of Neurological Disorders and...TerminatedTraumatic Brain InjuryUnited States
-
University of Texas, El PasoRecruitingKnee Osteoarthritis | Knee Pain Chronic | Central Pain SyndromeUnited States
-
Aksaray University Training and Research HospitalCompletedExercise Training | Lactate Blood Increase | Cognitive Functions | BDNFTurkey (Türkiye)
-
University of Alabama at BirminghamCompletedCystic FibrosisUnited States
-
University of LisbonFundação para a Ciência e a TecnologiaActive, not recruiting
-
University of Missouri-ColumbiaCompleted
-
University of AlcalaCompletedMyofascial Pain | Myofascial Pain Syndrome | Post Needling Soreness | Myofascial Trigger Point PainSpain
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada
-
University College CorkRecruitingDepressive Disorder, MajorIreland
-
Sahmyook UniversityRecruitingChronic Nonspecific Neck PainKorea, Republic of